Esperion Logo (primary).png
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 04, 2022 16:05 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on August 2, 2022, the Compensation Committee of Esperion’s Board of Directors granted 13 new...
Esperion Logo (primary).png
Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update
August 02, 2022 07:00 ET | Esperion Therapeutics, Inc.
– Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial; On Track for Topline Results 1Q 2023 – – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and...
Esperion Logo (primary).png
Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors
November 01, 2021 07:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Seth H.Z. Fischer as a Class III director, with a term expiring at the 2022 meeting of...
Esperion Logo (primary).png
Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement
June 22, 2020 07:00 ET | Esperion Therapeutics, Inc.
Esperion to Receive $150 Million Milestone Payment in June Esperion Completes Transfer of Marketing Authorization Approvals (MAAs) for NILEMDO™ (bempedoic acid) and NUSTENDI™ (bempedoic acid and...
Esperion Logo (primary).png
Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Sessions
June 14, 2020 09:30 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 14, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analysis from four Phase 3 clinical studies of NEXLETOL were presented at the American...
Esperion Logo (primary).png
Esperion to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference
June 08, 2020 08:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 08, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside...
Esperion Logo (primary).png
Esperion to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference 2020
May 27, 2020 08:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside...
Esperion Logo (primary).png
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 15, 2020 18:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on May 15, 2020, the Compensation Committee of Esperion’s Board of Directors granted 88,902...
Esperion Logo (primary).png
Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference
May 07, 2020 08:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside...
Esperion Logo (primary).png
Esperion Reports First Quarter 2020 Financial Results and Provides Company Update
May 06, 2020 16:05 ET | Esperion Therapeutics, Inc.
Company Secures Marketing Approvals for NEXLETOL™ and NEXLIZET™ Tablets in the U.S. as well as for NILEMDO™ and NUSTENDI™ Tablets in EuropeNEXLETOL™ (bempedoic acid) Tablets Commercially Available in...